Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD). Albuminuria and estimated glomerular filtration rate (eGFR) are currently recognized clinical indicators for early diagnosis of DN, however, the sensitivity and specificity are unsatisfactory. The early identification and treatment of DKD are conducive to lowering the risk of kidney damage by as much as 50%. Therefore, it is particularly critical to find new biomarkers to reflect the potential DKD lesions in the clinical silent period earlier and more accurately. Therefore, this study intends to analyze the differentially expressed lipids in early DKD, T2DM and healthy adults by mass spectrometry, and verify the related results by larger samples, so as to screen out early markers of DKD and achieve the ultimate goal of clinical application.
Eligibility Criteria
Inclusion Criteria: 1. Subjects who have signed informed consent. 2. Subjects were 20-80 years old and of either gender. 3. Subjects showed good compliance, and the follow-up data was available for \>5 years. Exclusion Criteria: 1. Meet the 1999 World Health Organization (WHO) diagnostic criteria for T1DM、T2DM; 2. Renal diseases caused by other causes, including primary and secondary; 3. All kinds of acute infections; 4. The expected life expectancy (life expectancy or related diseases) was less than 5 years according to the researcher's judgment. 5. Drug users or drug abusers; 6. Sexually transmitted diseases such as viral hepatitis, AIDS and syphilis, and infectious diseases such as tuberculosis are in an active period; 7. Any situation judged by the researcher that affects enrollment.